On 29 January 2024, Kinarus Therapeutics Holding AG in liquidation (Kinarus) announced that it has entered into a transaction agreement (Transaction Agreement) with Curatis AG (Curatis) regarding a contemplated combination transaction. Curatis is a privately owned specialty pharmaceutical company focusing predominantly on orphan/ultra-orphan diseases and specialty care diseases. Under the terms of the Transaction Agreement, shareholders of Curatis shall exchange each outstanding Curatis share into one newly issued Kinarus share, whereby the consideration consists of approx.

14x the number of outstanding Kinarus shares. It is planned that Kinarus will be renamed to Curatis Holding AG. The transaction is expected to close in Q2 2024. Closing is subject to certain closing conditions, inter alia, confirmation of withdrawal of bankruptcy for Kinarus by the courts of Basel-Stadt, approval of all proposed resolutions by the extraordinary general meeting of Kinarus and approval of the listing of the new shares by SIX Swiss Exchange.